« Home

Home » Chemistry » Patrick: An Introduction to Medicinal Chemistry 4e » Student resources » Hyperlinked bibliography » Chapter 12

Patrick: An Introduction to Medicinal Chemistry 4e

Chapter 12

Further reading

Bleicher, K. H., et al. (2003) Hit and lead generation: beyond high-throughput screening. Nature Reviews Drug Discovery, 2, 369-378 [DOI: 10.1038/nrd1086] [PubMed: 12750740].

Blundell, T. L., Jhoti, H., and Abell, C. (2002) High-throughput crystallography for lead discovery in drug design. Nature Reviews Drug Discovery, 1, 45-54 [DOI: 10.1038/nrd706] [PubMed: 12119609].

Clardy, J., and Walsh, C. (2004) Lessons from natural molecules. Nature, 432, 829-837 [DOI: 10.1038/nature03194] [PubMed: 15602548].

Engel, L. W., and Straus, S. E. (2002) Development of therapeutics: opportunities within complementary and alternative medicine. Nature Reviews Drug Discovery, 1, 229-237 [DOI: 10.1038/nrd750] [PubMed: 12120507].

Gershell, L. J., and Atkins, J. H. (2003) A brief history of novel drug discovery technologies. Nature Reviews Drug Discovery, 2, 321-327 [DOI: 10.1038/nrd1064] [PubMed: 12669031].

Honma, T. (2003) Recent advances in de novo design strategy for practical lead identification. Medicinal Research Reviews, 23, 606-632 [DOI: 10.1002/med.10046] [PubMed: 12789688].

Hopkins, A. L., and Groom, C. R. (2002) The druggable genome. Nature Reviews Drug Discovery, 1, 727-730 [DOI: 10.1038/nrd892] [PubMed: 12209152].

Lewis, R. J., and Garcia, M. L. (2003) Therapeutic potential of venom peptides. Nature Reviews Drug Discovery, 2, 790-802 [DOI: 10.1038/nrd1197] [PubMed: 14526382].

Lindsay, M. A. (2003) Target discovery. Nature Reviews Drug Discovery, 2, 831-838 [DOI: 10.1038/nrd1202] [PubMed: 14526386].

Lipinski, C., and Hopkins, A. (2004) Navigating chemical space for biology and medicine. Nature, 432, 855-861 [DOI: 10.1038/nature03193] [PubMed: 15602551].

O’shannessy, D. J., et al. (1993) Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. Anal. Biochem., 212, 457-468 [DOI: 10.1006/abio.1993.1355].

Pellecchia, M., Sem, D. S., and Wuthrich, K. (2002) NMR in drug discovery. Nature Reviews Drug Discovery, 1, 211-219 [DOI: 10.1038/nrd748] [PubMed: 12120505].

Rees, D. C., et al. (2004). Fragament-based lead discovery, 3, 660-672.

Rishton, G. B. (2003) Nonleadlikeness and leadlikeness in biochemical screening. Discovering. Drugs Today, 8, 86-96 [DOI: 10.1016/S1359644602025722].

Sauter, G., Simon, R., and Hillan, K. (2003) Tissue microarrays in drug discovery. Nature Reviews Drug Discovery, 2, 962-972 [DOI: 10.1038/nrd1254] [PubMed: 14654795].

Shuker, S. B., Hajduk, P. J., Meadows, R. P., and Fesik, S. W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science, 274, 1531-1534 [DOI: 10.1126/science.274.5292.1531] [PubMed: 8929414].

Stockwell, B. R. (2004) Exploring biology with small organic molecules. Nature, 432, 846-854 [DOI: 10.1038/nature03196] [PubMed: 15602550].

Su, J., et al. (2007) SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: taming hERG. Bioorganic and Medicinal Chemistry, 15, 5369-85 [DOI: 10.1016/j.bmc.2007.05.068] [PubMed: 17572094].

Walters, W. P., and Namchuk, M. (2003) Designing screen: how to make your hits a hit. Nature Reviews Drug Discovery, 2, 259-266 [DOI: 10.1038/nrd1063] [PubMed: 12669025].

Wermuth, C. G. (2006) Selective optimization of side activities: the SOSA approach. Drug Discovery Today, 11, 160-164 [DOI: 10.1016/S1359-6446(05)03686-X].